RenovoRx increases RenovoCath production, expands Medical Murray partnership with warrant for 709,500 shares

RenovoRx, Inc.

RenovoRx boosts production of FDA-cleared RenovoCath catheter due to strong physician demand; over 500 procedures performed.
New work order with Medical Murray; RenovoRx issues warrant for up to 709,500 shares to incentivize manufacturing milestones.
Phase III TIGeR-PaC trial in pancreatic cancer continues; 52nd event (interim analysis) expected late 2024 or early 2025.
CEO expects commercial launch of RenovoCath as standalone device to generate revenue during 2025; sufficient cash on hand.
Robert Strasser promoted to VP of R&D and Operations to lead manufacturing and commercial strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.